Posts Tagged ‘Fracture Risk’
The American Society of Clinical Oncology received bad news about Breast Cancer Patients this week. A study of women with breast cancer, being treated with Aromatase Inhibitors (AI), was presented at the 2014 Breast Cancer Symposium. AI is a great treatment for breast cancer, however…
AI is known to decrease bone strength and to increase Fracture Risk. How many of these patients were evaluated for their bone health? Only 54%. How many got a repeat evaluation to check to be sure that their bone health was not deteriorating? Only 46%.
Of those tested, 43% had a DXA T-score in the “osteopenia” range. In this situation, FRAX is needed to calculate Fracture Risk. 41% of this group met guidelines for treatment with medication to prevent bone loss and Fractures. Of those who should have been treated, only 23% were.
Running your butt off several days weekly, as a child, is good for your bones. And the benefits last a lifetime!
We already knew that vigorous running sports can produce a peak bone mass and bone size at least 50% better than couch potatoes’. Now a study, in the Scandinavian Journal of Medicine and Science in Sports, of elderly individuals has shown that these traits persist long after retirement from sports. Fracture rates and Fracture Risk are also lower in former athletes.
Aromatase Inhibitors (AI) do a great job treating Breast Cancers which are Estrogen dependent. The AI wipe out all Estrogen thereby depriving the breast cancer of a needed stimulus.
Unfortunately, Aromatase Inhibitor treatment will also do considerable damage to your bones unless you take medication to protect your bones. The good news is that we have medication which can completely offset the harm AI treatment could do to your bones. But, you have to take it, and the sooner you start, the better.
Denosumab (Prolia) mimics the natural process that keeps OsteoClasts (the cells that gobble up bone) under control before menopause. OsteoCytes release Osteoprotegrin (OPG) when Estrogen (or Testosterone) is on board. OPG controls the formation and activation of OsteoClasts by blocking RANK-Ligand, which is necessary for OsteoClast formation and activation. This decreases fracture risk.